Oxybutynin (OXB) is one of the most used medications to treat urinary incontinence especially in older population. Because of the first pass metabolism which produce the active metabolite N-Desethyl-Oxybutynin the reason for adverse side effects especially dry mouth, topical gel formulations were developed using Carbopol ETD2020 (0.5%, 1%), Poloxamer 407 (2%) , Hydroxy Ethyl Cellulose HEC (1%, 2%), Hydroxy Propyl Methyl Cellulose HPMC (2%, 4%). These formulations were evaluated for drug content, pH determination, viscosity measurement at 25oC and 37oC, and for in-vitro drug release using Enhancer Cell, In order to reach the best formulation, which is effective, and can reduces the adverse side effects. Then a comparison was made with the brand product. Among all the prepared formulations, F1 and F2 formulations prepared by using 0.5% and 1% Carbopol ETD2020 respectively, were the best because they exhibited the best in-vitro drug release, and there were no statistical differences in the drug release from F1 and F2 formulations and the drug release from the brand product